Last €2.44 EUR
Change Today -0.041 / -1.65%
Volume 0.0
BT3 On Other Exchanges
Symbol
Exchange
BT3 is not on other exchanges.
As of 2:08 AM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

biotime inc (BT3) Snapshot

Open
€2.43
Previous Close
€2.48
Day High
€2.46
Day Low
€2.43
52 Week High
01/17/14 - €3.09
52 Week Low
05/9/14 - €1.62
Market Cap
179.6M
Average Volume 10 Days
406.0
EPS TTM
--
Shares Outstanding
73.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTIME INC (BT3)

biotime inc (BT3) Related Businessweek News

No Related Businessweek News Found

biotime inc (BT3) Details

BioTime, Inc., a biotechnology company, is engaged in the research and product development in the field of regenerative medicine. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, cGMP-capable human embryonic stem cell lines, and differentiation kits, as well as offers Hextend, a blood plasma volume expander to treat hypovolemia in surgery, emergency trauma treatment, and other applications. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; and stem cell-based therapies for retinal and neurological disorders. It also develops HyStem hydrogels, such as ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and Premvia, a hydrogel formulation to manage wounds, as well as PanC-Dx, a non-invasive cancer products for use in detecting breast, bladder, and lung cancers. In addition, the company markets GeneCards, a human gene database. Further, it is developing an integrated database suite to complement GeneCards that would include the LifeMap database of embryonic development, stem cell research, and regenerative medicine, as well as MalaCards, the human disease database. Additionally, the company develops cell based therapeutic products for diseases, such as neurological disorders, age related macular degeneration, orthopedic disorders, and cardiovascular disease and related ischemic disorders. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.

106 Employees
Last Reported Date: 03/17/14
Founded in 1990

biotime inc (BT3) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $745.3K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $550.1K
Chief Commercial Officer
Total Annual Compensation: $315.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $104.2K
Compensation as of Fiscal Year 2013.

biotime inc (BT3) Key Developments

BioTime Receives FDA Premarket Notification Clearance for Premvia(TM) 510(k)

BioTime, Inc. announced that it has received notice from the FDA's Center for Devices and Radiologic Health that Premvia(TM) has been cleared for marketing as a Class II medical device. Premvia(TM) is the first FDA-cleared member of BioTime's HyStem(R) family of hydrogels, which are designed to mimic the natural structures of the human body's extracellular matrix. According to the FDA clearance, the product is indicated for the management of wounds including: partial thickness, full-thickness, tunneling wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, donor skin graft sites, post-Moh's surgery, post-laser surgery, podiatric wounds, wound dehiscence, abrasions, lacerations, second degree burns, skin tears and draining wounds. The clearance of Premvia(TM) in the United States will provide BioTime with a foundation for the development of even more advanced bioactive and cell-matrix combination products. The pivotal trial of Renevia(TM) (another HyStem(R) -based product) is expected to begin later this year in Europe, where BioTime is seeking a CE Mark for the use of Renevia(TM) in combination with cells for the purpose of lipotransfer in the treatment of HIV-related lipoatrophy. BioTime also is in the process of developing HyStem(R) technology for use in formulating a number of products manufactured from pluripotent stem cells using the Company's proprietary PureStem(R) technology. Combination products of HyStem(R) -based hydrogels with PureStem(R) cell lines will require future human clinical trials.

BioTime, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

BioTime, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss attributable to the company were $9,520,190 or $0.16 per basic and diluted share on total revenue of $1,106,700 against net loss attributable to the company were $7,549,765 or $0.14 per basic and diluted share on total revenue of $1,216,325 a year ago. Loss from operations was $13,061,674 compared to $8,116,451 a year ago. Loss before income tax benefit was $12,906,966 against $8,195,613 a year ago. For the six months, the company reported net loss attributable to the company were $17,608,835 or $0.29 per basic and diluted share on total revenue of $2,173,260 against net loss attributable to the company were $15,282,391 or $0.29 per basic and diluted share on total revenue of $1,824,290 a year ago. Loss from operations was $24,182,748 compared to $16,520,186 a year ago. Loss before income tax benefit was $23,966,854 against $16,628,894 a year ago. The increase in revenue is primarily attributable to a $0.4 million increase in grant income primarily from a grant awarded to BioTime's subsidiary Cell Cure Neurosciences Ltd. The increase in net loss is primarily attributed to increased research and development related activity primarily in Asterias, LifeMap Solutions, and Cell Cure Neurosciences.

BioTime, Inc. Announces Auditor Changes

BioTime, Inc. announced that Rothstein Kass is no longer providing accounting and audit services and on June 30, 2014 Rothstein Kass resigned as the independent registered public accounting firm. On July 7, 2014, the board of directors approved the engagement of OUM & Co. LLP as the new independent registered public accounting firm.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BT3:GR €2.44 EUR -0.041

BT3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Cell Technology Inc $7.41 USD -0.54
Athersys Inc $1.39 USD +0.02
Geron Corp $2.00 USD -0.16
NeoStem Inc $5.53 USD -0.29
Neuralstem Inc $3.28 USD -0.17
View Industry Companies
 

Industry Analysis

BT3

Industry Average

Valuation BT3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.2x
Price/Book 15.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIME INC, please visit www.biotimeinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.